{
    "nct_id": "NCT05714345",
    "official_title": "A Randomized, Open-Label, Phase 2 Study Evaluating Lymphodepletion With ALLO-647, Fludarabine, and Cyclophosphamide, vs. Fludarabine and Cyclophosphamide Alone, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy",
    "inclusion_criteria": "* Histologically confirmed diagnosis of relapsed/refractory large B-cell lymphoma at last relapse\n* Relapsed or refractory disease after at least 2 lines of chemotherapy\n* ECOG performance status 0 or 1\n* Absence of significant donor (product)-specific anti-HLA antibodies (DSA)\n* Adequate hematological, renal and liver function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active central nervous system involvement by malignancy\n* Autologous or allogeneic HSCT within last 6 months prior to lymphodepletion\n* Hypocellular bone marrow for age",
    "miscellaneous_criteria": ""
}